Abstract:Inhibition of acetylcholinesterase (AChE) is a crucial target in the treatment of Alzheimer's disease (AD). Common anti-acetylcholinesterase drugs such as Galantamine, Rivastigmine, Donepezil, and Tacrine have significant inhibition potential. Due to side effects and safety concerns, we aimed to investigate a wide range of phytochemicals and structural analogues of these compounds. Compounds similar to the established drugs, and phytochemicals were investigated as potential inhibitors for AChE in treating AD. A total of 2,270 compound libraries were generated for further analysis. Initial virtual screening was performed using Pyrx software, resulting in 638 molecules showing higher binding affinities compared to positive controls Tacrine (-9.0 kcal/mol), Donepezil (-7.3 kcal/mol), Galantamine (-8.3 kcal/mol), and Rivastigmine (-6.4 kcal/mol). Subsequently, ADME properties were assessed, including blood-brain barrier permeability and Lipinski's rule of five violations, leading to 88 compounds passing the ADME analysis. Among the rivastigmine analogous, [3-(1-methylpiperidin-2-yl)phenyl] N,N-diethylcarbamate showed interaction with Tyr123, Tyr336, Tyr340, Phe337, Trp285 residues of AChE. Tacrine similar compounds, such as 4-amino-2-styrylquinoline, exhibited bindings with Tyr123, Phe337, Tyr336, Trp285, Trp85, Gly119, and Gly120 residues. A phytocompound (bisdemethoxycurcumin) showed interaction with Trp285, Tyr340, Trp85, Tyr71, and His446 residues of AChE with favourable binding. These findings underscore the potential of these compounds as novel inhibitors of AChE, offering insights into alternative therapeutic avenues for AD. A 100ns simulation analysis confirmed the stability of protein-ligand complex based on the RMSD, RMSF, ligand properties, PCA, DCCM and MMGBS parameters. The investigation suggested 3 ligands as a potent inhibitor of AChE which are [3-(1-methylpiperidin-2-yl)phenyl] N,N-diethylcarbamate, 4-Amino-2-styrylquinoline and bisdemethoxycurcumin. Furthermore, investigation, including in-vitro and in-vivo studies, is needed to validate the efficacy, safety profiles, and therapeutic potential of these compounds for AD treatment.

Inhibition of Human Acetylcholinesterase by Cyclophosphamide

Thermodynamic Investigation of Camel Retina Acetylcholinesterase Inhibition by Cyclophosphamide.

Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach

Multiple Approaches to Analyse the Data for Rat Brain Acetylcholinesterase Inhibition by Cyclophosphamide

Thermodynamic Analysis of Human Retinal Acetylcholinesterase Inhibition Using an Anti-Alzheimer's Drug, Tacrine, Through the Development of a Dual Substrate and Temperature Model.

Interaction of human brain acetylcholinesterase with cyclophosphamide: a molecular modeling and docking study.

The inhibitory effect of cyclophosphamide on camel retina acetylcholinesterase activity.

On the Inhibition of Camel Retina Acetylcholinesterase Activity by Cycloheximide in Vitro

Kinetics of Human Erythrocyte Acetylcholinesterase Inhibition by Cis-Diamminediaquaplatinum (Ii)

Human Erythrocyte Acetylcholinesterase Inhibition by Cis-Diamminediaquaplatinum (II): a Novel Kinetic Approach

Optimization and Kinetic Studies of Human Erythrocyte Membrane-Bound Acetylcholinesterase

The Toxicity Of Methylenecyclopropylglycine: Studies Of The Inhibitory Effects Of (Methylenecyclopropyl)Formyl-Coa On Enzymes Involved In Fatty Acid Metabolism And The Molecular Basis Of Its Inactivation Of Enoyl-Coa Hydratases

The Preparation and Kinetic Analysis of Multiple Forms of Human Erythrocyte Acetylcholinesterase

Binding Analysis of Some Classical Acetylcholinesterase Inhibitors: Insights for a Rational Design Using Free Energy Perturbation Method Calculations with QM/MM MD Simulations

Elucidating the molecular mechanism of noncompetitive inhibition of acetylcholinesterase by an antidiabetic drug chlorpropamide: identification of new allosteric sites

Kinetic Analysis of the Inhibition of Human Butyrylcholinesterase with Cymserine.

Characterization of Human Erythrocyte Membrane-Bound Acetylcholinesterase Inhibition by Cisplatin at Reversible Phase.

Estimation and Correlation of IC50 for the Inhibition of Human Erythrocyte Acetylcholinesterase by Cis-Diamminediaquaplatinum (II).

Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine.

Towards more effective acetylcholinesterase inhibitors: a comprehensive modelling study based on human acetylcholinesterase protein–drug complex

A computational approach to identify phytochemicals as potential inhibitor of acetylcholinesterase: Molecular docking, ADME profiling and molecular dynamics simulations